Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: A meta-analysis

Journal of Neurology

Volumn 261, Issue 6, 2014, Pages 1133-1138

  Abraham, Alon ^a,b   Drory, Vivian E ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Amyotrophic lateral sclerosis; Antioxidants; Inflammation; Motor neuron disease; Neurodegenerative diseases; Uric acid

Indexed keywords

URIC ACID;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; DEATH; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE DURATION; FORCED VITAL CAPACITY; HUMAN; KIDNEY FUNCTION; MEDLINE; META ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; URIC ACID BLOOD LEVEL; BLOOD; FEMALE; MALE; MORTALITY; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA;

AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; HUMANS; MALE; PROGNOSIS; PUBMED; SEX FACTORS; URIC ACID;

EID: 84903579488     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7331-x     Document Type: Article

References (39)

1. Johnson RJ, Gaucher EA, Sautin YY, Henderson GN, Angerhofer AJ, Benner SA (2008) The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease. Med Hypotheses 71:22-31
2. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:6858-6862
3. Kutzing MK, Firestein BL (2008) Altered uric acid levels and disease states. J Pharmacol Exp Ther 324:1-7
4. Alvarez-Lario B, Macarron-Vicente J (2011) Is there anything good in uric acid? QJM 104:1015-1024
5. Pak CY, Moe OW, Sakhaee K, Peterson RD, Poindexter JR (2005) Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol 173:1606-1609
6. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH (2009) Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 61:225-232
7. Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56:95-100
8. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU (2006) Decreased plasma antioxidants in patients with Alzheimer's disease. Int J Geriatr Psychiatry 21:344-348
9. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6:23-28
10. Euser SM, Hofman A, Westendorp RG, Breteler MM (2009) Serum uric acid and cognitive function and dementia. Brain 132:377-382
11. Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, Tsoutsou A, Zournas C, Zissimopoulos V, Vassilopoulos D (2009) Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg 111:724-728
12. Chen H, Mosley TH, Alonso A, Huang X (2009) Plasma urate and Parkinson's disease in the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol 169:1064-1069
13. Winquist A, Steenland K, Shankar A (2010) Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey. Mov Disord 25:932-936
14. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797-800
15. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A (2007) Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166:561-567
16. O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A (2010) Plasma urate and Parkinson's disease in women. Am J Epidemiol 172:666-670
17. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM (1996) Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 144:480-484
18. Lee JE, Song SK, Sohn YH, Lee PH (2011) Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 26:1533-1536
19. Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington's disease progression. Mov Disord 25:224-228
20. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D (2006) Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 108:527-531
21. Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221-226
22. Guerrero AL, Martin-Polo J, Laherran E, Gutierrez F, Iglesias F, Tejero MA, Rodriguez-Gallego M, Alcazar C (2008) Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 15:394-397
23. Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, Logroscino G (2011) An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol 258:238-243
24. Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, Tsehori J, Nefussy B, Drory VE (2009) Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 285:95-99
25. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y (2012) Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 51:1501-1508
26. Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, Wills AM (2012) Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259:1923-1928
27. Kataoka H, Kiriyama T, Kobayashi Y, Horikawa H, Ueno S (2013) Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged ≥70 years. Am J Neurodegener Dis 2:140-144
28. Zoccolella S, Palagano G, Fraddosio A, Russo I, Ferrannini E, Serlenga L, Maggio F, Lamberti S, Iliceto G (2002) ALS-plus: 5 cases of concomitant amyotrophic lateral sclerosis and parkinsonism. Neurol Sci 23(Suppl 2):S123-S124
29. Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55:463-472
30. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci USA 80:4546-4550
31. Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA (2012) Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS One 7:e37331
32. Gersch C, Palii SP, Imaram W, Kim KM, Karumanchi SA, Angerhofer A, Johnson RJ, Henderson GN (2009) Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 28:118-149
33. Santos CX, Anjos EI, Augusto O (1999) Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 372:285-294
34. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95:675-680
35. Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC (2000) The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 165:6511-6518
36. Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D, Peric V, Dragutinovic G, Marinkovic J, Levic Z, Mostarica Stojkovic M (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248:121-126
37. Alvarez-Lario B, Macarron-Vicente J (2010) Uric acid and evolution. Rheumatology (Oxford) 49:2010-2015
38. Gonsette RE, Sindic C, D'Hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455-462
39. Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, de Antonelle Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K (2013) Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 71(2):141-150